Core Insights - Nurix Therapeutics is advancing its Phase III trial for bexobrutideg, a targeted protein degrader, which represents a new class of therapeutics in the industry [2][3][4] - The company positions bexobrutideg as the first drug in its category, indicating a significant evolution in therapeutic approaches beyond traditional small molecule inhibitors and antibodies [3][4] Company Overview - Arthur Sands serves as the President and CEO of Nurix Therapeutics, leading the discussion on the company's innovative drug development [1] - The company emphasizes the importance of targeted protein degraders in the context of evolving therapeutic modalities, suggesting a strategic focus on this new mechanism of action (MOA) [3][4] Industry Context - The presentation highlights the transition from traditional therapies, such as small molecule inhibitors and DNA-based therapeutics, to a new class of drugs represented by targeted protein degraders [3][4] - The introduction of bexobrutideg is seen as a potential game-changer in the therapeutic landscape, indicating a shift in how diseases may be treated in the future [4]

Core Insights - Nurix Therapeutics is advancing its Phase III trial design for its lead program, bexobrutideg, which represents a new class of therapeutics known as targeted protein degraders [2][3][4] - The company positions bexobrutideg as the first drug in this new mechanism of action (MOA), indicating its potential significance in the evolution of therapeutic options [3][4] Company Overview - Arthur Sands serves as the President and CEO of Nurix Therapeutics, leading the discussion on the company's innovative approaches [1][3] - The company emphasizes the transition from traditional therapies, such as small molecule inhibitors and antibodies, to a novel class of drugs that utilize targeted protein degradation [3][4]

Core Insights - Targeted protein degradation is an emerging field in drug development, with over 10 years of experience from the company [1] - The company is based in San Francisco and leverages scientific research from UCSF and Berkeley [1] - Targeted protein degraders are small molecules that can be taken orally to remove disease-causing proteins from cells [2] Industry Context - The development of targeted protein degradation is positioned alongside major breakthroughs in drug development, such as antibodies and nucleic acid-based therapies [2] - The primary goal of therapeutics has been to specifically target and eliminate disease-causing proteins [2]

Question-and-Answer SessionArthur SandsCEO, President & Director Well, thank you for having us. Happy to give you an introduction. These are our disclaimers. So yes, targeted protein degradation is a new field still, although we've been at it for over 10 years. We're based in San Francisco and the Bay Area based on science out of UCSF and Berkeley. And what's pictured on the slide is this evolution of new therapeutic modalities. So we are in targeted protein degradation, which focuses on the removal of prot ...

Core Insights - The discussion focuses on targeted protein degradation as an evolving therapeutic modality that offers advantages over traditional therapies like antibodies and nucleic acid-based treatments [2][3]. Company Overview - Nurix is positioned within the landscape of therapeutics, emphasizing the effectiveness of targeted protein degradation in removing whole proteins and multiple classes of proteins [3][4]. - The company highlights the benefits of its small molecule approach, which allows for oral administration and once-a-day dosing [3]. Industry Context - The presentation contrasts targeted protein degradation with existing modalities, noting that while antibodies and nucleic acid-based therapies have been successful, they come with certain limitations [2][4]. - The potential for targeted protein degraders to achieve antibody-like efficacy while being more convenient to administer is underscored [4].

Group 1 - The discussion focuses on targeted protein degradation as an evolving therapeutic modality, highlighting its place among successful treatments like antibodies and nucleic acid-based therapies [2][3] - Targeted protein degraders represent a small molecule approach that can effectively remove entire proteins, offering advantages such as oral administration and once-a-day dosing [3][4] - This method is positioned as having antibody-like or biologic-like efficacy, potentially surpassing the effectiveness of traditional nucleic acid-based therapies and antibodies [4]

PresentationTerence FlynnEquity Analyst All right. Great. Good morning. Thanks for joining us, everybody. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. Very pleased to be kicking off the third day of our conference this morning, hosting Nurix, and we have Arthur Sands, the company's President and CEO. Thanks so much, Arthur. Before we get started, just for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have ...

Company Overview - Nurix is being hosted at a conference by Morgan Stanley, with Arthur Sands serving as the President and CEO [1] - The conference aims to discuss the company's current standing and strategic priorities [2]

Summary of Nurix Therapeutics FY Conference Call Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Date**: September 10, 2025 - **Key Speaker**: Arthur T. Sands, President and CEO Core Industry and Company Insights Pipeline and Programs - Nurix is entering pivotal studies for its lead program, Bexobrutide (BexDeg), targeting chronic lymphocytic leukemia (CLL) [2] - The company is planning Phase 2 and 3 studies for BexDeg, with recent design considerations disclosed for the Phase 3 study [2][20] - Other programs include NX-2127 and NX-1607, focusing on aggressive lymphomas and immuno-oncology targets, respectively [2][3] - The company has a partnership with Sanofi for a STAT6 degrader and with Gilead for an IRAK4 degrader, both in IND-enabling studies [3][54] Platform and Technology - Nurix's platform is based on E3 ligases and has evolved to include a DEL-AI platform for ligand discovery, allowing for rapid development across oncology and inflammation [5][6] - The platform enables the development of degrader antibody conjugates (DACs), with a partnership with Pfizer [7] Safety and Efficacy of BexDeg - BexDeg has shown no drug-related atrial fibrillation above background levels, indicating a favorable cardiovascular profile compared to other BTK inhibitors [18] - The design of BexDeg aims for high selectivity and potency, which is expected to translate into better efficacy and safety [14] Pivotal Trial Design - The pivotal trial for BexDeg includes a single-arm study for accelerated approval in a third-line plus population, with a randomized control trial planned as a confirmatory study [20][21] - Key endpoints for the accelerated approval include overall response rate (ORR) and progression-free survival (PFS), with an observed ORR of about 80% in earlier trials [22][23] - The market opportunity for the third-line plus patient population is estimated to be between 8,000 to 10,000 patients in the U.S., with significant revenue potential [25] Future Aspirations - Nurix is considering combination therapies for earlier lines of treatment, with plans for a Phase 1B/2 study combining BexDeg with venetoclax and anti-CD20 antibodies [36] - The company is currently self-funding its studies but is open to partnerships for future combination studies [38] Financial Position - Nurix has a cash runway extending into the first half of 2027, with approximately $485 million in cash as of the last quarter [61] Additional Insights - The company is actively participating in upcoming medical conferences to present data on its various programs, including ESMO and ASH [42][45] - The STAT6 program with Sanofi is expected to enter healthy volunteer studies by 2026, pending Sanofi's timeline [56] This summary encapsulates the key points discussed during the conference call, highlighting Nurix Therapeutics' strategic priorities, pipeline developments, and market opportunities.

Nurix Therapeutics (NasdaqGM:NRIX) 2025 Conference September 09, 2025 10:50 AM ET Company ParticipantsArthur Sands - President, CEO, and Board DirectorConference Call ParticipantsBrian Skorney - Senior Biotech AnalystBrian SkorneyMorning, everyone. Thank you for joining our next session. I'm Brian Skorney. I'm one of Baird's Senior Biotech Analysts. I'm very happy to have with us presenting Nurix. It's a company that I cover. I'm very excited about the working in the protein degradation space. They have a l ...